News
-
Threshold Pharmaceuticals Earns $20M Milestone Payment From Merck KGaA For Positive Results From Phase 2 Trial Of TH-302 In Pancreatic Cancer
4/12/2012
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced it has earned a $20 million milestone payment from Merck KGaA, Darmstadt, Germany, for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled Phase 2 clinical trial ("404 trial") evaluating the efficacy and safety of two doses of TH-302, a hypoxia-targeted drug, in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer.
-
XARELTO (rivaroxaban) Demonstrates Comparable Efficacy To Standard Of Care For The Treatment And Secondary Prevention Of Venous Blood Clots In Patients With Symptomatic Pulmonary Embolism In Pivotal Phase 3 Study
3/27/2012
Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO (rivaroxaban) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).
-
Shire To Acquire FerroKin BioSciences, Inc., And Its Phase 2 Iron Chelator Treatment
3/19/2012
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
-
Data In NEJM Shows Novartis Drug Signifor Is First Therapy To Provide Rapid, Durable Benefit For Cushing's Disease Patients In Phase III Study
3/9/2012
A study published in The New England Journal of Medicine (NEJM) found that the investigational drug Signifor (SOM230, pasireotide), normalized cortisol levels and showed clinical benefit in patients with Cushing's disease.
-
OGT Releases First In A New Line Of Cancer Microarrays
3/8/2012
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has released the first in a number of new microarrays for use in cancer research.
-
Isis Adds Three New Drugs To Its Development Pipeline
12/16/2011
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.
-
Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765
12/14/2011
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced recently that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.
-
New Phase III Data Shows Novartis JAK Inhibitor INC424 Significantly Reduced Disease Burden In Patients With Myelofibrosis
12/14/2011
Novartis recently announced additional results from two pivotal Phase III trials evaluating Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in myelofibrosis.
-
New Partnership To Create Research And Commercial Manufacturing Hub At UC Davis In Sacramento
10/12/2011
UC Davis Health System, PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., and Northern California PET Imaging Center (NCPIC) announced recently that they will partner to establish a facility on the university's Sacramento campus for research and training in radiochemistry and for the commercial production of radiopharmaceutical products used in positron emission tomography (PET) scans -- an imaging technique that provides molecular information important for diagnosing disease and conducting clinical research.
-
LabCorp To Offer A New Companion Diagnostic For Non-Small Cell Lung Cancer
10/7/2011
Laboratory Corporation of America Holdings (LabCorp) announced recently the nationwide availability of a new FDA-approved companion diagnostic for lung cancer patients.
This website uses cookies to ensure you get the best experience on our website. Learn more